Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin

Summary

The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of bismuth quadruple therapy with cefuroxime and levofloxacin for Helicobacter pylori eradication. After 6 weeks of treatment, subjects underwent another 13C urea breath test. Eradication rates, adverse reaction rates and patient compliance were calculated.

Timeline

Start

2024-04

Primary completion

2024-12

Completion

2024-12

Outcome

Met primary endpoint

paper Noninferiority of the Cef-Tet BQT group was demonstrated in all three analyses (p < 0.0001). PMID 40237213 ↗

Publications

• Wang H, Kong Q, Zhang Q, Zhang L, Li R, Zhang T, Guo L, Wang X, Li X, Zhao H, Liu F, Guo Y, Zhai Z, Li M, Yang X, Zuo X, Yang X, Li Y. Efficacy and Safety of Cefuroxime-Tetracycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Penicillin-Allergic Patients: A Multicenter Randomized Controlled Trial. Helicobacter. 2025 Mar-Apr;30(2):e70033. doi: 10.1111/hel.70033.

Drugs

Indications